Can Novo Nordisk (NYSE:NVO) Trade Below Fair Value On Earnings?

Novo Nordisk has seen its share price fall sharply in recent years, which puts fresh focus on whether the current US$40.00 level is still aligned with what its earnings can justify. With new obesity and diabetes treatments in the headlines and tougher competition emerging, the question is how much of that story is already baked into the stock.

• The share price has declined 56.7% over the past 3 years, which raises the issue of whether the earnings profile now better matches the current market valuation.

• Management is pushing a broader pipeline that includes CagriSema and other GLP-1 related candidates, which can influence how investors think about future profit potential and the durability of Novo Nordisk’s earnings base.

• There is a second opinion on Novo Nordisk worth weighing. See what analysts think Novo Nordisk’s shares could be worth.

The issue now is whether Novo Nordisk’s present share price is supported by the earnings that the business is generating today and is expected to produce over time.

If you want a wider view of how other healthcare names stack up on similar themes of obesity, diabetes and GLP-1 exposure, a focused stock screen is a useful second starting point for research through 34 healthcare AI stocks.

Is Novo Nordisk Still Cheap on Earnings?

P/E is the cleanest yardstick here because earnings remain the main anchor investors use to frame Novo Nordisk and its obesity and diabetes franchise. On that measure, the stock trades on a P/E of 10.1x, which is well below the Pharmaceuticals sector average of 16.0x and far under the peer group on 61.3x. For a business still heavily associated with GLP-1 therapies, that is a low headline earnings multiple relative to many rivals in the space.

The fair P/E that drops out of the model, which blends factors like profitability profile, scale and risk, sits well above where Novo Nordisk trades today. As a result, the current 10.1x screens as undervalued on this framework. Because Citi has flagged tougher GLP-1 competition from Eli Lilly, the discount suggests the market is already pricing in a fair amount of that pressure while leaving room for upside if Novo Nordisk’s broader pipeline delivers more than investors currently expect. Explore the numbers behind Novo Nordisk’s P/E valuation.

The Novo Nordisk Narrative: What Would Justify Today’s Price?

Novo Nordisk Narratives pick up where the P/E puzzle leaves off by spelling out what would need to happen to growth, margins and earnings for the stock to look materially higher or lower than today’s price, and they sit on Simply Wall St’s Community page. Rather than leaning on a single multiple or model, each one lays out the assumptions behind its fair value so you can track those against Novo Nordisk’s actual results over time.